Search

Your search keyword '"Fu, Ziyi"' showing total 16 results
Start Over Author "Fu, Ziyi" Publisher wiley
16 results on '"Fu, Ziyi"'

1. Efficacy and safety of the proposed bevacizumab biosimilar BAT1706 compared with reference bevacizumab in patients with advanced nonsquamous non‐small cell lung cancer: A randomized, double‐blind, phase III study

Author

Chen, Likun, primary, Rangel, Jose David Gomez, additional, Cil, Timucin, additional, Li, Xingya, additional, Cicin, Irfan, additional, Shen, Yihong, additional, Liu, Zhihua, additional, Ozyilkan, Ozgur, additional, Igor, Bondarenko, additional, Chen, Jun, additional, Oleksandr, Kostiuk, additional, Chen, Zhendong, additional, Zhang, Helong, additional, Fu, Ziyi, additional, Dong, Qingfeng, additional, Song, Shuqiang, additional, Yu, Jin‐Chen, additional, and Zhang, Li, additional

Published
2023
Full Text
View/download PDF

2. N4‐Acetylcytidine Drives Glycolysis Addiction in Gastric Cancer via NAT10/SEPT9/HIF‐1α Positive Feedback Loop (Adv. Sci. 23/2023)

Author

Yang, Qingbin, primary, Lei, Xuetao, additional, He, Jiayong, additional, Peng, Yanmei, additional, Zhang, Yihao, additional, Ling, Ruoyu, additional, Wu, Chaorui, additional, Zhang, Guofan, additional, Zheng, Boyang, additional, Chen, Xinhua, additional, Zou, Boya, additional, Fu, Ziyi, additional, Zhao, Liying, additional, Liu, Hao, additional, Hu, Yanfeng, additional, Yu, Jiang, additional, Li, Fengping, additional, Ye, Gengtai, additional, and Li, Guoxin, additional

Published
2023
Full Text
View/download PDF

3. Nonmetastatic breast cancer patients subsequently developing second primary malignancy: A population‐based study

Author

Bao, Shengnan, primary, Jiang, Mengping, additional, Wang, Xi, additional, Hua, Yijia, additional, Zeng, Tianyu, additional, Yang, Yiqi, additional, Yang, Fan, additional, Yan, Xueqi, additional, Sun, Chunxiao, additional, Yang, Mengzhu, additional, Fu, Ziyi, additional, Huang, Xiang, additional, Li, Jun, additional, Wu, Hao, additional, Li, Wei, additional, Tang, Jinhai, additional, and Yin, Yongmei, additional

Published
2021
Full Text
View/download PDF

4. Relationship between tRNA ‐derived fragments and human cancers

Author

Zeng, Tianyu, primary, Hua, Yijia, additional, Sun, Chunxiao, additional, Zhang, Yuchen, additional, Yang, Fan, additional, Yang, Mengzhu, additional, Yang, Yiqi, additional, Li, Jun, additional, Huang, Xiang, additional, Wu, Hao, additional, Fu, Ziyi, additional, Li, Wei, additional, and Yin, Yongmei, additional

Published
2020
Full Text
View/download PDF

9. EPHA5 mediates trastuzumab resistance in HER2‐positive breast cancers through regulating cancer stem cell‐like properties

Author

Li, Yongfei, primary, Chu, Jiahui, additional, Feng, Wanting, additional, Yang, Mengzhu, additional, Zhang, Yanhong, additional, Zhang, Yanqiu, additional, Qin, Ye, additional, Xu, Juan, additional, Li, Jun, additional, Vasilatos, Shauna N., additional, Fu, Ziyi, additional, Huang, Yi, additional, and Yin, Yongmei, additional

Published
2019
Full Text
View/download PDF

11. miRNA profiling in the hippocampus of attention‐deficit/hyperactivity disorder rats

Author

Tian, Tian, primary, Zhang, Yan, additional, Wu, Tianqi, additional, Yang, Lei, additional, Chen, Chunxiao, additional, Li, Nan, additional, Li, Yue, additional, Xu, Siliang, additional, Fu, Ziyi, additional, Cui, Xianwei, additional, Ji, Chenbo, additional, Chi, Xia, additional, Tong, Meiling, additional, Chen, Ronghua, additional, Hong, Qin, additional, and Hu, Youfang, additional

Published
2018
Full Text
View/download PDF

14. Cancer/testis antigen‐Plac1 promotes invasion and metastasis of breast cancer through Furin/ NICD / PTEN signaling pathway

Author

Li, Yongfei, primary, Chu, Jiahui, additional, Li, Jun, additional, Feng, Wanting, additional, Yang, Fan, additional, Wang, Yifan, additional, Zhang, Yanhong, additional, Sun, Chunxiao, additional, Yang, Mengzhu, additional, Vasilatos, Shauna N., additional, Huang, Yi, additional, Fu, Ziyi, additional, and Yin, Yongmei, additional

Published
2018
Full Text
View/download PDF

16. Candidate Oligo Therapeutic Target, miR-330-3p, Induces Tamoxifen Resistance in Estrogen Receptor-Positive Breast Cancer Cells via HDAC4.

Author

Zhang M, Wang M, Jiang Z, Fu Z, Ma J, and Gao S

Subjects
Humans, Female, Tamoxifen pharmacology, Tamoxifen therapeutic use, Receptors, Estrogen, Histone Deacetylases genetics, Repressor Proteins, Breast Neoplasms drug therapy, Breast Neoplasms genetics, MicroRNAs genetics
Abstract

Tamoxifen is a drug used for treating breast cancer (BC), especially for individuals diagnosed with estrogen receptor-positive (ER+) BC. Its prolonged use could reduce the risk of recurrence and significantly lengthen the survival rate of BC patients. However, an increasing number of patients developed resistance to tamoxifen treatment, which reduced therapeutic efficiency and caused substandard prognosis. Therefore, the exploration of the molecular processes involved in tamoxifen resistance (TR) is urgently required. This investigation aimed to elucidate the relationship of microRNA-330 (miR-330-3p) with the TR of BC. There is little information on miR-330-3p's link with drug-resistant BC, although it is well known to regulate cell proliferation and apoptosis. Primarily, miR-330-3p expression in parental BC (MCF7/T47D), TR (MCF7-TR), and T47D/TR cell lines was detected by qRT-PCR. Then, the impact of miR-330-3p on the TR of BC cells was assessed by a cell proliferation assay. Lastly, dual-luciferase reporter, qRT-PCR, and western blot assessments were carried out to identify histone deacetylase 4 (HDAC4) as the potential miR-330-3p target gene. The data indicated that miRNA-330 was overexpressed in TR ER+ BC cells and its overexpression could induce TR. Furthermore, miRNA-330 could also reduce the expression of HDAC4, which is closely linked to TR, and overexpression of HDAC4 could reverse miRNA-330-induced drug resistance. In summary, miR-330-3p could induce TR of ER+ BC cells by downregulating HDAC4 expression, which might be a novel marker of TR and a possible treatment target against BC patients who are tamoxifen-resistant., Competing Interests: The authors declare that they have no conflicts of interest., (Copyright © 2023 Meng Zhang et al.)

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results